ButiShield™ - Butyrate for the Intestine and Beyond

ButiShield™ is an encapsulated low odor source of calcium butyrate safe for daily consumption that provides a targeted release of >35% butyric acid.  Butyrate is a short chain fatty acid with science-based health benefits for strength, health, and integrity of the intestinal wall, leading to extra-intestinal health benefits.

Butyrate works by serving as a primary energy source for healthy intestinal cells and supports intestinal barrier integrity^1-5. Butyrate also works by helping shape a healthy microbiome and gastrointestinal environment^6-9 and serves as a signaling molecule to regulate numerous metabolic processes at the cellular level^10-15.

ButiShield may offer the following benefits*:

• Helps shape a healthy microbiome and gastrointestinal environment^7-9
• Primary energy source for healthy intestinal cells^2-5
• Support of a healthy intestinal barrier integrity^2-5
• Promotes a healthy gastrointestinal environment^6-9

Next Generation Encapsulation Technology

ButiShield is produced using MicroPEARLS®,  a proprietary spray-freezing technology which helps to mask the typical unpleasant odor of butyric acid and promote a targeted, slow release in the gastrointestinal (GI) tract to deliver butyric acid where it delivers maximum benefit. For over 60 years, Kemin has designed, finetuned, validated and mastered our encapsulation technologies. Our cutting edge MicroPEARLS technology with butyrate has serviced the animal health industry for years and today Kemin has elevated it to the next level in human health.

Product Attributes

Targeted release, low odor, Kosher, Halal, Non-GMO, Gluten-free, Allergen-free, Vegetarian , Proprietary encapsulation technology

Ready to Set Your Gut Health Product Apart with ButiShield?

Complete the form, and a Kemin representative will get in touch soon.

*These statements have not been evaluated by the US Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease. The information on this webpage is a business-to-business information and not intended for the final consumer. Certain statements may not be applicable in all geographical regions. Product labeling and associated claims differs based upon government requirements and country or region specific information should also be considered when labeling or advertising to final consumers. This web page and its associated brochures and other documents do not constitute or provide scientific or medical advice, diagnosis, or treatment and are distributed without warranty of any kind, either expressly or implied. This web page, its title or contents and associated brochures and other documents do not in any way make recommendations for health or marketing claims by the reader. Country and region specific regulations should be considered in this regard. Each claim or statement about the effectiveness of Kemin products and/or each claim or statement comparing the effectiveness of Kemin products to the effectiveness of other products is expressly limited to the United States, unless otherwise disclosed on the Kemin websites.

References

1. Banasiewicz T, Domagalska D, Borycka-Kiciak K, Rydzewska G. Determination of butyric acid dosage based on clinical and experimental studies – a literature review. Gastroenterology Review/Przegląd Gastroenterologiczny. 2020;15(2):119-125. doi:10.5114/pg.2020.95556.
2. Donohoe, D.R., Garge, N., Zhang, X., Sun, W., O'Connell, T.M., Bunger, M.K. and Bultman, S.J., 2011. The microbiome and butyrate regulate energy metabolism and autophagy in the mammalian colon. Cell metabolism, 13(5), pp.517-526.
3. Yan, H. and Ajuwon, K.M., 2017. Butyrate modifies intestinal barrier function in IPEC-J2 cells through a selective upregulation of tight junction proteins and activation of the Akt signaling pathway. PloS one, 12(6), p.e0179586.
4. Peng, L., Li, Z.R., Green, R.S., Holzman, I.R. and Lin, J., 2009. Butyrate enhances the intestinal barrier by facilitating tight junction assembly via activation of AMP-activated protein kinase in Caco-2 cell monolayers. The Journal of nutrition, 139(9), pp.1619-1625.
5. Bach Knudsen, K.E., Lærke, H.N., Hedemann, M.S., Nielsen, T.S., Ingerslev, A.K., Gundelund Nielsen, D.S., Theil, P.K., Purup, S., Hald, S., Schioldan, A.G. and Marco, M.L., 2018. Impact of diet-modulated butyrate production on intestinal barrier function and inflammation. Nutrients, 10(10), p.1499.
6. Facchin, S., Vitulo, N., Calgaro, M., Buda, A., Romualdi, C., Pohl, D., Perini, B., Lorenzon, G., Marinelli, C., D’Incà, R. and Sturniolo, G.C., 2020. Microbiota changes induced by microencapsulated sodium butyrate in patients with inflammatory bowel disease. Neurogastroenterology & Motility, 32(10), p.e13914.
7. Gao, F., Lv, Y.W., Long, J., Chen, J.M., He, J.M., Ruan, X.Z. and Zhu, H.B., 2019. Butyrate improves the metabolic disorder and gut microbiome dysbiosis in mice induced by a high-fat diet. Frontiers in Pharmacology, 10, p.1040.
8. Louis, P. and Flint, H.J., 2009. Diversity, metabolism and microbial ecology of butyrate-producing bacteria from the human large intestine. FEMS microbiology letters, 294(1), pp.1-8.
9. Vital, M., Karch, A. and Pieper, D.H., 2017. Colonic butyrate-producing communities in humans: an overview using omics data. Msystems, 2(6), pp.e00130-17.
10. Davie, J.R., 2003. Inhibition of histone deacetylase activity by butyrate. The Journal of nutrition, 133(7), pp.2485S-2493S.
11. Furusawa, Y., Obata, Y., Fukuda, S., Endo, T.A., Nakato, G., Takahashi, D., Nakanishi, Y., Uetake, C., Kato, K., Kato, T. and Takahashi, M., 2013. Commensal microbe-derived butyrate induces the differentiation of colonic regulatory T cells. Nature, 504(7480), pp.446-450.
12. Inan, M.S., Rasoulpour, R.J., Yin, L., Hubbard, A.K., Rosenberg, D.W. and Giardina, C., 2000. The luminal short-chain fatty acid butyrate modulates NF-κB activity in a human colonic epithelial cell line. Gastroenterology, 118(4), pp.724-734.
13. Patnala, R., Arumugam, T.V., Gupta, N. and Dheen, S.T., 2017. HDAC inhibitor sodium butyrate-mediated epigenetic regulation enhances neuroprotective function of microglia during ischemic stroke. Molecular Neurobiology, 54(8), pp.6391-6411.
14. Zhang, M., Wang, Y., Zhao, X., Liu, C., Wang, B. and Zhou, J., 2021. Mechanistic basis and preliminary practice of butyric acid and butyrate sodium to mitigate gut inflammatory diseases: a comprehensive review. Nutrition Research, 95, pp.1-18.
15. Kasubuchi, M., Hasegawa, S., Hiramatsu, T., Ichimura, A. and Kimura, I., 2015. Dietary gut microbial metabolites, short-chain fatty acids, and host metabolic regulation. Nutrients, 7(4), pp.2839-2849
16. Sperber, A.D., Bangdiwala, S.I., Drossman, D.A., Ghoshal, U.C., Simren, M., Tack, J., Whitehead, W.E., Dumitrascu, D.L., Fang, X., Fukudo, S. and Kellow, J., 2021. Worldwide prevalence and burden of functional gastrointestinal disorders, results of Rome Foundation Global Study. Gastroenterology, 160(1), pp.99-114.
17. https://nutrition.org/most-americans-are-not-getting-enough-fiber-in-our-diets
18. Madison and Kiecolt-Glaser. Current opinion in behavioral sciences 28 (2019): 105-110.